A-1155463: a Bcl-X(L) inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 59447577 |
| CHEMBL ID | 3342332 |
| SCHEMBL ID | 2501550 |
| MeSH ID | M000612786 |
| Synonym |
|---|
| bdbm50030754 |
| chembl3342332 , |
| S7800 |
| SCHEMBL2501550 |
| 3cq , |
| 2-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1h)-yl]-5-(3-{4-[3-(dimethylamino)prop-1-yn-1-yl]-2-fluorophenoxy}propyl)-1,3-thiazole-4-carboxylic acid |
| a-1155463 |
| 1235034-55-5 |
| HY-19725 |
| CS-5398 |
| EX-A1060 |
| AKOS030526342 |
| 2-[8-[(2-benzothiazolylamino)carbonyl]-3,4-dihydro-2(1h)-isoquinolinyl]-5-[3-[4-[3-(dimethylamino)-1-propyn-1-yl]-2-fluorophenoxy]propyl]-4-thiazolecarboxylic acid |
| mfcd29924714 |
| 2-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1h)-yl)-5-(3-(4-(3-(dimethylamino)prop-1-yn-1-yl)-2-fluorophenoxy)propyl)thiazole-4-carboxylic acid |
| a1155463 |
| BCP18309 |
| BS-14688 |
| a 1155463 |
| CCG-270355 |
| Q27453707 |
| 2-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluorophenoxy]propyl]-1,3-thiazole-4-carboxylic acid |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | IC50 (µMol) | 0.3820 | 0.0010 | 0.5763 | 4.3000 | AID1791972; AID1914432 |
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | Ki | 0.0780 | 0.0000 | 0.1901 | 2.9000 | AID1168932; AID1293719; AID1914433 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Homo sapiens (human) | Ki | 0.7940 | 0.0000 | 0.2108 | 5.6234 | AID1914437 |
| Translocator protein | Rattus norvegicus (Norway rat) | Ki | 0.7941 | 0.0001 | 0.6510 | 8.9300 | AID1794444 |
| Delta-type opioid receptor | Homo sapiens (human) | Ki | 2.1249 | 0.0000 | 0.5978 | 9.9300 | AID1794423; AID1914426 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Ki | 1.1189 | 0.0000 | 0.7411 | 9.9000 | AID1794410; AID1914438 |
| Bcl-2-like protein 1 | Homo sapiens (human) | IC50 (µMol) | 0.0005 | 0.0003 | 1.0482 | 9.5400 | AID1791971; AID1913236 |
| Bcl-2-like protein 1 | Homo sapiens (human) | Ki | 0.0000 | 0.0000 | 0.4581 | 9.0000 | AID1168930; AID1168931; AID1293720 |
| Induced myeloid leukemia cell differentiation protein Mcl-1 | Homo sapiens (human) | Ki | 0.4400 | 0.0010 | 1.4653 | 9.5400 | AID1168941 |
| Sigma intracellular receptor 2 | Homo sapiens (human) | Ki | 0.8084 | 0.0001 | 0.8360 | 4.6005 | AID1794446; AID1914439 |
| Bcl-2-like protein 2 | Homo sapiens (human) | Ki | 0.0190 | 0.0010 | 1.2590 | 8.1900 | AID1168940 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 0.1359 | 0.0000 | 0.4901 | 10.0000 | AID1794447; AID1914434 |
| Histamine H3 receptor | Homo sapiens (human) | Ki | 1.8111 | 0.0001 | 0.3399 | 8.5110 | AID1794428; AID1914424 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Bcl-2-like protein 1 | Homo sapiens (human) | EC50 (µMol) | 0.0650 | 0.0100 | 0.0337 | 0.0650 | AID1912781 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1168936 | Cmax in SCID-Beige mouse at 5 mg/kg, ip | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. |
| AID1853850 | Cytotoxicity against human MOLT-4 cells assessed as cell growth inhibition incubated for 72 hrs | 2022 | European journal of medicinal chemistry, Mar-15, Volume: 232 | Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment. |
| AID1168931 | Inhibition of BCL-XL (unknown origin) incubated for 1 hr in presence of 1% human serum by TR-FRET assay | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. |
| AID1168932 | Inhibition of BCL-2 (unknown origin) incubated for 1 hr by TR-FRET assay | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. |
| AID1168939 | Drug concentration in SCID-Beige mouse at 5 mg/kg, ip after 12 hrs | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. |
| AID1853851 | Cytotoxicity against human platelets assessed as cell growth inhibition incubated for 24 hrs | 2022 | European journal of medicinal chemistry, Mar-15, Volume: 232 | Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment. |
| AID1168940 | Binding affinity to BCL-W (unknown origin) | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. |
| AID1168938 | AUC in SCID-Beige mouse at 5 mg/kg, ip | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. |
| AID1168937 | Tmax in SCID-Beige mouse at 5 mg/kg, ip | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. |
| AID1168942 | Reduction in platelets count in SCID-Beige mouse at 5 mg/kg, ip after 6 hrs | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. |
| AID1293724 | Cytotoxicity against human Bcl-XL dependant MOLT4 cells by cell based assay | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9 | Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity. |
| AID1168935 | Cytotoxicity against BCL-XL-dependent human NCI-H146 cells in presence of 10% human serum incubated for 48 hrs by Cell titerGlo reagent based assay | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. |
| AID1293725 | Cytotoxicity against human Bcl-2 dependant RS4:11 cells by cell based assay | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9 | Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity. |
| AID1293720 | Binding affinity to Bcl-XL (unknown origin) by FRET assay | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9 | Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity. |
| AID1168933 | Selectivity index, ratio of Ki for BCL-2 (unknown origin) to Ki for BCL-XL (unknown origin) | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. |
| AID1293719 | Binding affinity to Bcl-2 (unknown origin) by FRET assay | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9 | Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity. |
| AID1168930 | Inhibition of BCL-XL (unknown origin) incubated for 1 hr by TR-FRET assay | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. |
| AID1168941 | Binding affinity to MCL1 (unknown origin) | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. |
| AID1168944 | Antitumor activity against BCL-XL-dependent human NCI-H146 cells xenografted in SCID-Beige mouse assessed as tumor growth inhibition at 5 mg/kg, ip for 14 days | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. |
| AID1168943 | Reduction in platelets count in SCID-Beige mouse at 5 mg/kg, ip after 72 hrs | 2014 | ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.46) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (13.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (86.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||